CN102716097A - Method for controlling medicament release rate of orally disintegrating tablet - Google Patents
Method for controlling medicament release rate of orally disintegrating tablet Download PDFInfo
- Publication number
- CN102716097A CN102716097A CN2012101788997A CN201210178899A CN102716097A CN 102716097 A CN102716097 A CN 102716097A CN 2012101788997 A CN2012101788997 A CN 2012101788997A CN 201210178899 A CN201210178899 A CN 201210178899A CN 102716097 A CN102716097 A CN 102716097A
- Authority
- CN
- China
- Prior art keywords
- preparing
- agent
- active component
- mix homogeneously
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention relates to a preparation method of an orally disintegrating tablet. The orally disintegrating tablet contains active ingredients, a water-insoluble film-forming material accounting for 0.1%-4% of the total weight of the tablet and other pharmaceutically acceptable additives, and is prepared through a wet granulation process. The orally disintegrating tablet prepared according to the method disclosed by the invention can control the release rate of the active ingredients and is favorable for ensuring the bioequiavailability, clinical safety and efficacy of a product. Furthermore, the method disclosed by the invention has the advantages of simple process flow and easiness in realization of industrial production.
Description
Technical field
The present invention relates to field of pharmaceutical preparations, particularly relate to oral cavity disintegration tablet.
Background technology
Oral cavity disintegration tablet (Orally disintegrating tablets); Being called for short oral cavity disintegration tablet, is that a kind of water that in the oral cavity, do not need can quickly disintegrated tablet, can not need the water assisting deglutition when taking; Need not to chew; Tablet places on the tongue, meets the rapid disintegrate of saliva, relies on to swallow the onset of power entering gastrointestinal absorption.With respect to conventional tablet, oral cavity disintegration tablet especially is fit to the patient's medication under dysphagia person (particularly old man, child) or the special environment that can not obtain water.
Oral cavity disintegration tablet improves bioavailability because its quickly disintegrated characteristic has very fast dissolution rate usually, and a large amount of documents has reported that all oral cavity disintegration tablet can improve the dissolution rate of product.For example the Li Yun prunus mume (sieb.) sieb.et zucc. points out that oral cavity disintegration tablet has the high characteristics of bioavailability in progress (Heilungkiang medicine, the Vol.23 No.3 2010 427-429) literary composition of oral cavity disintegration tablet in Chinese medicine preparation.Can solve the slow problem of insoluble drug dissolution velocity, thereby accelerate infiltration rate, also can make low dosage, water soluble drug oral and hypoglossis mucous membrane that molecular weight is less directly absorb human blood, have avoided first pass effect, thereby have improved bioavailability.Come little pellet etc. in progress (2009 the 18th volumes of Chinese Pharmaceutical the 19th a phase 78-79) literary composition of oral cavity disintegration tablet, also point out oral cavity disintegration tablet because of taking convenience, rapid-action, bioavailability is high, the good tablet that becomes of mouthfeel is developed the focus in the focus.Thank to cloudling etc. and point out also that in progress (medical Leader 2009 the 28th volumes the 9th a phase 1179-1181) literary composition of oral cavity disintegration tablet oral cavity disintegration tablet compares with conventional tablet, have and absorb fast, advantages such as bioavailability is high, taking convenience, intestinal is residual less, untoward reaction is little, part is avoided the liver first pass effect, topical therapeutic is effective.
This quickening dissolution rate of oral cavity disintegration tablet, people are needed just in some cases for the characteristics of raising bioavailability, but in other cases, accelerate dissolution rate in vitro, improve the characteristics of bioavailability and also can bring adverse influence.For example when imitation medicine exploitation or dosage changing form research; With the contrast medicine bioequivalence be vital; Have only with the bioequivalent product of contrast medicine just possibly obtain the listing permission through examining, and because the characteristic of the quick stripping of oral cavity disintegration tablet; When the contrast medical instrument has slower dissolution rate, often be difficult to reach bioequivalence.The release and the absorption rate that also possibly need the control medicine in the clinical research of new drug are to reach ideal safety and effectiveness.This all need control release rate of drugs in the prescription research of medicament.Here said control drug release speed is not to make medicine become slow release by rapid release, and only is in reasonable range, to slow down release rate of drugs, makes its external stripping curve and the external stripping curve of contrast medicine mate (similar factors f2＞50).
The method of conventional control drug release speed normally increases binder dosage, reduces the disintegrating agent consumption, prolongs disintegration time, increases the particle diameter of active component, and active component is carried out coating etc., but the common inapplicable and oral cavity disintegration tablet of these methods.Because oral cavity disintegration tablet requires disintegrate in the 1min in the oral cavity, increase binder dosage, reduce the disintegrating agent consumption and all can cause the disintegration time overrun; And being carried out coating, active component uses the powder coating technology; Technical difficulty is bigger, and to behind the active component coating, it is big that granularity becomes; Have grains of sand sense, influence mouthfeel.The particle diameter that increases active component is only applicable to the medicine of big specification, and also can influence mouthfeel.For small dose drug, increase the active component particle diameter and can cause the uniformity of dosage units of product defective.
Therefore, still be necessary to provide a kind of easy, blanket method is controlled the active component rate of release of oral cavity disintegration tablet.
Summary of the invention
The invention provides a kind of method for preparing of oral cavity disintegration tablet; Said oral cavity disintegration tablet contains active component, accounts for water-insoluble filmogen and other the pharmaceutically acceptable additives of tablet total weight amount 0.1%-4%, and prepares through the step that following method comprises:
Method one:
(a) with active component, water-insoluble filmogen and filler, disintegrating agent mix homogeneously;
(b) add organic solvent granulation and drying and obtain dried granule;
(c) dried granule adds lubricant, and compacting in flakes behind the mix homogeneously;
Method two:
(a) with active component and filler, disintegrating agent mix homogeneously;
(b) the solution granulation and the drying of the organic solvent of adding water-insoluble filmogen obtain dried granule;
(c) dried granule adds lubricant, and compacting in flakes behind the mix homogeneously;
Method three:
(a) with active component and filler, disintegrating agent mix homogeneously;
(b) the aqueous dispersion granulation and the drying of adding water-insoluble filmogen obtain dried granule;
(c) dried granule adds lubricant, and compacting in flakes behind the mix homogeneously;
According to the present invention, the water-insoluble filmogen is selected from ethyl cellulose, polymethacrylates.
According to the present invention, organic solvent is selected from ethanol, isopropyl alcohol, acetone.
According to the present invention; The aqueous dispersion of water-insoluble filmogen can be selected commercially available aqueous dispersion; You Teqi
aqueous dispersion L 30D-55 for example; RL 30D; RS 30D; NE 30D, FS 30D, or Sulisi
Aquacoat; Also can be the aqueous dispersion of preparing voluntarily, for example 10 parts of polymethacrylates, 1 part of sodium lauryl sulphate and 1.5 parts of stearic acid are scattered in about 80 parts of water, can obtain the aqueous dispersion of polymethacrylates; Or can the methacrylate powder be added in the entry, add in the alkali part and the carboxyl of polymer, be mixed with aqueous dispersion.
According to the present invention, method one～three step (a), (c) can further add pharmaceutically acceptable additive by demand, like fluidizer, correctives, coloring agent, solubilizing agent, effervescent.
According to the present invention, method one～three step (c) can further add filler, disintegrating agent by demand.When the preparation granule, add partially filled dose, disintegrating agent; And the remaining filler of adding, disintegrating agent are the conventional ways of this area in the dried granule before tabletting; Cui Fude chief editor's " pharmaceutics " (the 5th edition for example; 117 pages) mention " the adding mode of disintegrating agent has outer addition, interior addition and inside and outside addition, that is: 1. outer addition is that disintegrating agent is incorporated in the tabletting dried granule before, and the disintegrate of tablet will occur between the granule; 2. interior addition is that disintegrating agent is incorporated in the pelletization, and the disintegrate of tablet occurs in granule interior; 3. inside and outside addition adds a part in being, adds a part, can make the disintegrate of tablet not only occur in granule interior but also occur between the granule, thereby reaches good disintegrate effect." this outer addition, interior addition and inside and outside addition equally also be applicable to filler (diluent), binding agent etc., in order to physical properties such as the flowability of improving material, compressibility.
Preparation in accordance with the present invention; Through wet granulation and exsiccant process, the water-insoluble filmogen can form little, discontinuous film on the surface of active component microgranule, reduces the contact area of active component and dissolution medium; Thereby hinder the release of active component to a certain extent; The rate of release that slows down, but because the film that forms is discontinuous, so can not cause active component not discharge fully.And with respect to powder coating technology, the technology of wet granulation is easier, and production efficiency is higher, also controls product quality more easily.
The water-insoluble filmogen is after oral cavity disintegration tablet is met water, and filmogen can not dissolve generation viscosity, can not cause the oral cavity disintegration tablet disintegrate slack-off yet.And it is opposite; If use water miscible binding agent or water soluble film-forming material, though also can control the rate of release of active component to a certain extent, after oral cavity disintegration tablet is met water; Binding agent or filmogen can dissolve generation viscosity; Hinder the further infiltration of water, and then cause the disintegrate of oral cavity disintegration tablet slack-off, even possibly cause disintegrate defective.
The used active component of oral cavity disintegration tablet of the present invention has no particular limits, and is used for treatment or prevent disease as long as it can be used as active constituents of medicine, and allows oral administration.For example can be the nutritional supplementation medicine, antipyretic-antalgic anti-inflammatory agent, antiviral agents, psychosis, hypnotic and sedative, spasmolytic, central nervous system's medicine; The brain metabolism improving medicine, cerebral circulation improves medicine, antuepileptic, sympathomimetic, digestive and stomachic, antiulcerative, gastrointestinal movement improves medicine; Antacid, antisussive and expectorant agent, bowel movement inhibitor, antiemetic, respiration stimulant, bronchodilator, antiallergic agent; Hydryllin, cardiac tonic, antiarrhythmics, diuretic, ACE inhibitor, Ca antagonist; The AII antagonist, vasoconstrictor, Coronary Vasodilators, vasodilation, peripheral vasodilator, antihyperlipidemic; Choleretic, cephem antibiotics, Perorally administrable antimicrobial medicine, chemotherapeutant, sulfonylureas, α glucosidase inhibitor; Agent for amelioration of insulin resistance, Semilente Insulin succagoga, DPPIV inhibitor, diabetes complicated Remedies, anti-sclerotin aerating agent, rheumatism; Skeletal muscle relaxant, alkaloid anesthetics, sulfonamide, gout treatment agent, blood coagulation inhibitor, anti-malignant tumor agent etc.
Active component of the present invention can be salt or free form, as long as it is that pharmacy is acceptable.It can also be a solvate form thereof, for example alcohol solvent compound or hydrate etc.In addition, above-mentioned active component can use separately, or unites two kinds or more kinds of use.
More specifically; Active component can be olanzapine, lisinopril, ramipril, valsartan, irbesartan, Candesartan, iloperidone, agomelatine, duloxetine, Quetiapine, topiramate, paroxetine, risperidone, fluoxetine, silodosin, lasofoxifene, blonanserin, Febustat, labetalol, sotalol, levetiracetam, amfebutamone, clopidogrel, prasugrel, venlafaxine, desmethylvenlafaxine, Ji Xitating, lamotrigine, Ziprasidone, ranolazine, tadanafil, paroxetine, handkerchief Risperdal, ambrisentan, telmisartan, voriconazole, Aripiprazole, Entecavir etc., or its pharmaceutically acceptable salt or solvate etc.
According to the present invention, the amount of active component accounts for the 0.01%-50% of oral cavity disintegration tablet gross weight usually, is preferably 0.1%-40%, more preferably 0.1%-25%.
According to the present invention, active component is normally through micronized, and to guarantee uniformity of dosage units and mouthfeel preferably, the mean diameter of preferred active component is less than 300 μ m, more preferably less than 200 μ m, more preferably less than 100 μ m.
According to the present invention; Pharmaceutically acceptable additive comprises filler (diluent), disintegrating agent, lubricant; Also can comprise other additives; As long as it pharmaceutically is being acceptable, and oral administered dosage form can be used for, for example fluidizer, correctives, coloring agent, solubilizing agent, effervescent etc. can also be comprised.
According to the present invention, filler is selected from microcrystalline Cellulose, Powderd cellulose, starch, pregelatinized Starch, dicalcium phosphate dehydrate, calcium phosphate dibasic anhydrous, calcium carbonate, calcium sulfate, magnesium carbonate, magnesium oxide, single water and milk sugar, Lactis Anhydrous, mannitol, xylitol, erythritol, sorbitol, fructose, glucose, sucrose etc.Whether dissolve in water according to filler; Can divide into water-soluble filler and water-insoluble filler, have mouthfeel preferably, alleviate grains of sand sense in order to make oral cavity disintegration tablet; The mean diameter of water-insoluble filler usually should be less than 250 μ m, more preferably less than 150 μ m; The particle diameter of water-soluble filler requires and can suitably relax, and for example mean diameter is preferably less than 300 μ m less than 500 μ m, more preferably less than 200 μ m.The ratio of control water-insoluble filler also can be improved the mouthfeel of oral cavity disintegration tablet, but the disintegration rate that may slow down, so the use amount of preferred water insoluble bulking agent accounts for the 5%-50% of filler total amount, more preferably 10%-35%.
According to the present invention, disintegrating agent is selected from cross-linking sodium carboxymethyl cellulose, carboxymethyl starch sodium, polyvinylpolypyrrolidone, low-substituted hydroxypropyl cellulose, carboxymethylcellulose calcium, sodium carboxymethyl cellulose.
According to the present invention, lubricant is selected from magnesium stearate, sodium stearyl fumarate, Polyethylene Glycol, Compritol 888 ATO.
According to the present invention; The use amount of additive is conventional; For example the consumption of disintegrating agent can be the 0.1%-30% that is equivalent to the tablet total weight amount; The consumption of lubricant can be the 0.01%-5% that is equivalent to the tablet total weight amount, and the consumption of filler can be arbitrarily, makes the total amount of tablet reach 100%.
According to the present invention, fluidizer is selected from silicon dioxide, colloidal silica, micropowder silica gel or Pulvis Talci.
According to the present invention, correctives is selected from aspartame, tartaric acid, vanillin, acesulfame potassium, cyclamate, artificial essence and citric acid.
According to the present invention, coloring agent comprises natural pigment and color lake, and wherein the color lake comprises ferrum oxide color lake and aluminum color lake.
According to the present invention, solubilizing agent is selected from sodium lauryl sulphate, poly yamanashi esters and polyoxyethylene fatty acid ester class.
According to the present invention, effervescent is the mixture that sodium bicarbonate and organic acid constitute in pairs, and organic acid is selected from citric acid, tartaric acid.
According to the present invention, have mouthfeel preferably in order to make oral cavity disintegration tablet, the tablet total weight amount of oral cavity disintegration tablet should be no more than 500mg, is preferably and is no more than 300mg.
The specific embodiment
The comparative example 1
Method for preparing: with Aripiprazole, microcrystalline Cellulose, pregelatinized Starch, mannitol, aspartame mix homogeneously; Adding an amount of dehydrated alcohol granulates; Obtain dried granule through fluid bed drying; Dried granule behind granulate with cross-linking sodium carboxymethyl cellulose, silicon dioxide, magnesium stearate mix homogeneously, compacting is in flakes.
Embodiment 1
Method for preparing: with Aripiprazole, microcrystalline Cellulose, pregelatinized Starch, mannitol, ethyl cellulose, aspartame mix homogeneously; Adding an amount of dehydrated alcohol granulates; Obtain dried granule through fluid bed drying; Dried granule behind granulate with cross-linking sodium carboxymethyl cellulose, silicon dioxide, magnesium stearate mix homogeneously, compacting is in flakes.
The sample of comparative example 1 and embodiment 1 is all used identical method (oar method 50rpm, pH1.0 hydrochloric acid solution 900mL) test stripping curve, and the result is following:
| Sample | 5 | 10 | 15 | 20 | 30 | 45 | 60 |
| The comparative example 1 | 88 | 96 | 98 | 99 | 100 | 100 | 100 |
| Embodiment 1 | 52 | 69 | 81 | 93 | 98 | 98 | 98 |
Embodiment 2
Method for preparing: with Aripiprazole, microcrystalline Cellulose, pregelatinized Starch, mannitol, ethyl cellulose, red ferric oxide, aspartame mix homogeneously; Adding an amount of dehydrated alcohol granulates; Obtain dried granule through fluid bed drying; Dried granule behind granulate with cross-linking sodium carboxymethyl cellulose, silicon dioxide, magnesium stearate mix homogeneously, compacting is in flakes.
Embodiment 3
Method for preparing: ethyl cellulose is dissolved in an amount of isopropyl alcohol; With Aripiprazole, calcium phosphate dibasic anhydrous, pregelatinized Starch, glucose, sucralose mix homogeneously; The aqueous isopropanol that adds ethyl cellulose is granulated; Obtain dried granule through fluid bed drying, dried granule behind granulate with cross-linking sodium carboxymethyl cellulose, micropowder silica gel, magnesium stearate mix homogeneously, compacting is in flakes.
Embodiment 4
Method for preparing: with Aripiprazole, sucrose, pregelatinized Starch, mannitol, tartaric acid mix homogeneously; Adding You Teqi
RL 30D granulates; Can extraly add an amount of dehydrated alcohol or water more as required; Obtain dried granule through fluid bed drying; Dried granule behind granulate with cross-linking sodium carboxymethyl cellulose, micropowder silica gel, magnesium stearate mix homogeneously, compacting is in flakes.
Embodiment 5
Method for preparing: with entecavir-monohydrate, microcrystalline Cellulose, ethyl cellulose, single water and milk sugar, aspartame; And the polyvinylpolypyrrolidone mix homogeneously of half amount; Adding an amount of dehydrated alcohol granulates; And use fluid bed drying, with remaining polyvinylpolypyrrolidone, micropowder silica gel, magnesium stearate mix homogeneously, compacting is in flakes behind granulate.
Embodiment 6
Method for preparing: ethyl cellulose is dissolved in an amount of dehydrated alcohol; With entecavir-monohydrate, microcrystalline Cellulose, single water and milk sugar, saccharin sodium mix homogeneously; The ethanol solution that adds ethyl cellulose is granulated; And use fluid bed drying, with mannitol, polyvinylpolypyrrolidone, colloidal silica, magnesium stearate mix homogeneously, compacting is in flakes behind granulate.
Embodiment 7
Method for preparing: with iloperidone, pregelatinized Starch, xylitol, sucralose mix homogeneously; Adding Sulisi
Aquacoat granulates; Can an amount of purified water of extra as required adding or dehydrated alcohol; And use fluid bed drying; With carboxymethyl starch sodium, silicon dioxide, magnesium stearate mix homogeneously, compacting in flakes behind granulate.
Embodiment 8
Method for preparing: with tadanafil, single water and milk sugar, microcrystalline Cellulose, acesulfame potassium mix homogeneously; Adding You Teqi
L30D-55 aqueous dispersion granulates; Can an amount of purified water of extra as required adding or dehydrated alcohol; And use fluid bed drying; With vanillin, cross-linking sodium carboxymethyl cellulose, micropowder silica gel, magnesium stearate mix homogeneously, compacting in flakes behind granulate.
Embodiment 9
Method for preparing: polymethacrylates is dissolved in the proper amount of acetone; With bisulfate clopidogrel, cane sugar powder, erythritol, pregelatinized Starch, low-substituted hydroxypropyl cellulose, tartaric acid mix homogeneously; The acetone soln that adds polymethacrylates is granulated; And use fluid bed drying, with micropowder silica gel, sodium stearyl fumarate mix homogeneously, compacting is in flakes behind granulate.
Embodiment 10
Method for preparing: with olanzapine, dicalcium phosphate dehydrate, cane sugar powder, low-substituted hydroxypropyl cellulose, polymethacrylates, sucralose, tartaric acid mix homogeneously; Add alcohol granulation; And use fluid bed drying; With cross-linking sodium carboxymethyl cellulose, micropowder silica gel, magnesium stearate mix homogeneously, compacting in flakes behind granulate.
Embodiment 11
Method for preparing: voriconazole, pregelatinized Starch, single water and milk sugar, ethyl cellulose, aspartame, tartaric acid mix homogeneously; Adding isopropyl alcohol granulates; And use fluid bed drying, with cross-linking sodium carboxymethyl cellulose, magnesium stearate mix homogeneously, compacting is in flakes behind granulate.
Claims (11)
1. the method for preparing of an oral cavity disintegration tablet; It is characterized in that said oral cavity disintegration tablet contains active component, accounts for water-insoluble filmogen and other the pharmaceutically acceptable additives of tablet total weight amount 0.1%-4%, and through being selected from the step preparation that one of following method comprises:
Method one:
(a) with active component, water-insoluble filmogen and filler, disintegrating agent mix homogeneously;
(b) add organic solvent granulation and drying and obtain dried granule;
(c) dried granule adds lubricant, and compacting in flakes behind the mix homogeneously;
Method two:
(a) with active component and filler, disintegrating agent mix homogeneously;
(b) the solution granulation and the drying of the organic solvent of adding water-insoluble filmogen obtain dried granule;
(c) dried granule adds lubricant, and compacting in flakes behind the mix homogeneously;
Method three:
(a) with active component and filler, disintegrating agent mix homogeneously;
(b) the aqueous dispersion granulation and the drying of adding water-insoluble filmogen obtain dried granule;
(c) dried granule adds lubricant, and compacting in flakes behind the mix homogeneously;
Wherein, the water-insoluble filmogen is selected from ethyl cellulose, poly-methyl acrylate.
2. method for preparing as claimed in claim 1 is characterized in that said organic solvent is selected from ethanol, isopropyl alcohol, acetone.
3. method for preparing as claimed in claim 1 is characterized in that method one～three step (a), (c) can further add pharmaceutically acceptable additive by demand, and said additive is selected from fluidizer, correctives, coloring agent, solubilizing agent, effervescent.
4. method for preparing as claimed in claim 1 is characterized in that method one～three step (c) can further add filler, disintegrating agent by demand.
5. like the method for preparing of claim 1 or 4, it is characterized in that said filler is selected from microcrystalline Cellulose, Powderd cellulose, starch, pregelatinized Starch, dicalcium phosphate dehydrate, calcium phosphate dibasic anhydrous, calcium carbonate, calcium sulfate, magnesium carbonate, magnesium oxide, single water and milk sugar, Lactis Anhydrous, mannitol, xylitol, erythritol, sorbitol, fructose, glucose, sucrose.
6. like the method for preparing of claim 1 or 4, it is characterized in that said disintegrating agent is selected from cross-linking sodium carboxymethyl cellulose, carboxymethyl starch sodium, polyvinylpolypyrrolidone, low-substituted hydroxypropyl cellulose, carboxymethylcellulose calcium, sodium carboxymethyl cellulose.
7. method for preparing as claimed in claim 1 is characterized in that said lubricant is selected from magnesium stearate, sodium stearyl fumarate, Polyethylene Glycol, Compritol 888 ATO.
8. method for preparing as claimed in claim 1 is characterized in that active component accounts for 0.01%～50% of tablet total weight amount, and the mean diameter of active component is less than 300 μ m.
9. method for preparing as claimed in claim 1 is characterized in that active component is selected from nutritional supplementation medicine, antipyretic-antalgic anti-inflammatory agent, antiviral agents, psychosis, hypnotic and sedative, spasmolytic; Central nervous system's medicine, the brain metabolism improving medicine, cerebral circulation improves medicine, antuepileptic, sympathomimetic, digestive and stomachic, antiulcerative; Gastrointestinal movement improves medicine, antacid, antisussive and expectorant agent, bowel movement inhibitor, antiemetic, respiration stimulant, bronchodilator; Antiallergic agent, hydryllin, cardiac tonic, antiarrhythmics, diuretic, ACE inhibitor, Ca antagonist; The AII antagonist, vasoconstrictor, Coronary Vasodilators, vasodilation, peripheral vasodilator, antihyperlipidemic; Choleretic, cephem antibiotics, Perorally administrable antimicrobial medicine, chemotherapeutant, sulfonylureas, α glucosidase inhibitor; Agent for amelioration of insulin resistance, Semilente Insulin succagoga, DPPIV inhibitor, diabetes complicated Remedies, anti-sclerotin aerating agent, rheumatism; Skeletal muscle relaxant, alkaloid anesthetics, sulfonamide, gout treatment agent, blood coagulation inhibitor, anti-malignant tumor agent.
10. method for preparing as claimed in claim 9; It is characterized in that active component is selected from olanzapine, lisinopril, ramipril, valsartan, irbesartan, Candesartan, iloperidone, agomelatine, duloxetine, Quetiapine, topiramate, paroxetine, risperidone, fluoxetine, silodosin, lasofoxifene, blonanserin, Febustat, labetalol, sotalol, levetiracetam, amfebutamone, clopidogrel, prasugrel, venlafaxine, desmethylvenlafaxine, Ji Xitating, lamotrigine, Ziprasidone, ranolazine, tadanafil, paroxetine, handkerchief Risperdal, ambrisentan, telmisartan, voriconazole, Aripiprazole, Entecavir, or its pharmaceutically acceptable salt or solvate.
11. the described method for preparing of claim 10 is characterized in that active component is an Aripiprazole.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101788997A CN102716097A (en) | 2012-05-29 | 2012-05-29 | Method for controlling medicament release rate of orally disintegrating tablet |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101788997A CN102716097A (en) | 2012-05-29 | 2012-05-29 | Method for controlling medicament release rate of orally disintegrating tablet |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102716097A true CN102716097A (en) | 2012-10-10 |
Family
ID=46942056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012101788997A Pending CN102716097A (en) | 2012-05-29 | 2012-05-29 | Method for controlling medicament release rate of orally disintegrating tablet |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102716097A (en) |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103191075A (en) * | 2013-04-28 | 2013-07-10 | 南京海融医药科技有限公司 | Oral medicinal preparation of tadalafil |
| CN103520131A (en) * | 2013-10-12 | 2014-01-22 | 浙江华海药业股份有限公司 | Preparation method of paroxetine hydrochloride semihydrate capsule |
| CN103751138A (en) * | 2013-12-31 | 2014-04-30 | 北京万全德众医药生物技术有限公司 | Orally disintegrating tablet containing lasofoxifene tartrate and preparation method thereof |
| CN103845297A (en) * | 2012-11-29 | 2014-06-11 | 倪伟华 | Carvedilol orally disintegrating tablet |
| CN104688694A (en) * | 2013-12-04 | 2015-06-10 | 长春海悦药业有限公司 | Pharmaceutical composition containing clopidogrel hydrogen sulfate |
| CN104887634A (en) * | 2015-05-07 | 2015-09-09 | 河北龙海药业有限公司 | Olanzapine orally disintegrating tablets and preparation method thereof |
| CN105213333A (en) * | 2014-06-30 | 2016-01-06 | 深圳海王药业有限公司 | A kind of tadanafil pharmaceutical composition and preparation method thereof |
| CN105832690A (en) * | 2016-05-12 | 2016-08-10 | 河北仁合益康药业有限公司 | Febuxostat coated tablet composition and preparation method thereof |
| CN106214650A (en) * | 2016-08-30 | 2016-12-14 | 扬子江药业集团南京海陵药业有限公司 | A kind of Voriconazole Dispersible Tablets and preparation method thereof |
| CN109419780A (en) * | 2017-09-04 | 2019-03-05 | 鲁南制药集团股份有限公司 | A kind of sotalol hydrochloride tablet and preparation method thereof |
| CN111110640A (en) * | 2018-10-31 | 2020-05-08 | 长春海悦药业股份有限公司 | Tadalafil tablet composition and preparation method thereof |
| CN112263555A (en) * | 2020-10-30 | 2021-01-26 | 重庆康刻尔制药股份有限公司 | Telmisartan orally disintegrating tablet and preparation method thereof |
| CN113952312A (en) * | 2021-10-24 | 2022-01-21 | 重庆市力扬医药开发有限公司 | Silodosin medicine absorbed through oral mucosa |
| CN115350178A (en) * | 2022-08-24 | 2022-11-18 | 浙江京新药业股份有限公司 | Pharmaceutical composition containing levetiracetam |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101227907A (en) * | 2005-05-03 | 2008-07-23 | 共有药物有限公司 | Quinine-containing controlled-release formulations |
| CN102026627A (en) * | 2008-03-11 | 2011-04-20 | 武田药品工业株式会社 | Orally-disintegrating solid preparation |
-
2012
- 2012-05-29 CN CN2012101788997A patent/CN102716097A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101227907A (en) * | 2005-05-03 | 2008-07-23 | 共有药物有限公司 | Quinine-containing controlled-release formulations |
| CN102026627A (en) * | 2008-03-11 | 2011-04-20 | 武田药品工业株式会社 | Orally-disintegrating solid preparation |
Non-Patent Citations (1)
| Title |
|---|
| 李笑慧等: "小儿用阿奇霉素口腔崩解片的制备及质量控制", 《中国药房》 * |
Cited By (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103845297A (en) * | 2012-11-29 | 2014-06-11 | 倪伟华 | Carvedilol orally disintegrating tablet |
| CN103191075A (en) * | 2013-04-28 | 2013-07-10 | 南京海融医药科技有限公司 | Oral medicinal preparation of tadalafil |
| CN103191075B (en) * | 2013-04-28 | 2015-04-08 | 南京海融医药科技有限公司 | Oral medicinal preparation of tadalafil |
| CN103520131A (en) * | 2013-10-12 | 2014-01-22 | 浙江华海药业股份有限公司 | Preparation method of paroxetine hydrochloride semihydrate capsule |
| CN103520131B (en) * | 2013-10-12 | 2019-05-14 | 浙江华海药业股份有限公司 | The preparation method of paroxetine hydrochloride semihydrate capsule |
| CN104688694A (en) * | 2013-12-04 | 2015-06-10 | 长春海悦药业有限公司 | Pharmaceutical composition containing clopidogrel hydrogen sulfate |
| CN104688694B (en) * | 2013-12-04 | 2018-09-11 | 长春海悦药业股份有限公司 | A kind of pharmaceutical composition containing bisulfate clopidogrel |
| CN103751138A (en) * | 2013-12-31 | 2014-04-30 | 北京万全德众医药生物技术有限公司 | Orally disintegrating tablet containing lasofoxifene tartrate and preparation method thereof |
| CN105213333A (en) * | 2014-06-30 | 2016-01-06 | 深圳海王药业有限公司 | A kind of tadanafil pharmaceutical composition and preparation method thereof |
| CN104887634B (en) * | 2015-05-07 | 2017-12-26 | 河北龙海药业有限公司 | Olanzapine oral disnitegration tablet and preparation method thereof |
| CN104887634A (en) * | 2015-05-07 | 2015-09-09 | 河北龙海药业有限公司 | Olanzapine orally disintegrating tablets and preparation method thereof |
| CN105832690A (en) * | 2016-05-12 | 2016-08-10 | 河北仁合益康药业有限公司 | Febuxostat coated tablet composition and preparation method thereof |
| CN106214650A (en) * | 2016-08-30 | 2016-12-14 | 扬子江药业集团南京海陵药业有限公司 | A kind of Voriconazole Dispersible Tablets and preparation method thereof |
| CN109419780A (en) * | 2017-09-04 | 2019-03-05 | 鲁南制药集团股份有限公司 | A kind of sotalol hydrochloride tablet and preparation method thereof |
| CN109419780B (en) * | 2017-09-04 | 2021-05-11 | 张家港市中医医院 | Sotalol hydrochloride tablet and preparation method thereof |
| CN111110640A (en) * | 2018-10-31 | 2020-05-08 | 长春海悦药业股份有限公司 | Tadalafil tablet composition and preparation method thereof |
| CN112263555A (en) * | 2020-10-30 | 2021-01-26 | 重庆康刻尔制药股份有限公司 | Telmisartan orally disintegrating tablet and preparation method thereof |
| CN113952312A (en) * | 2021-10-24 | 2022-01-21 | 重庆市力扬医药开发有限公司 | Silodosin medicine absorbed through oral mucosa |
| CN115350178A (en) * | 2022-08-24 | 2022-11-18 | 浙江京新药业股份有限公司 | Pharmaceutical composition containing levetiracetam |
| CN115350178B (en) * | 2022-08-24 | 2024-04-26 | 浙江京新药业股份有限公司 | Pharmaceutical composition containing levetiracetam |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102716097A (en) | Method for controlling medicament release rate of orally disintegrating tablet | |
| JP7028829B2 (en) | Orally disintegrating tablet and its manufacturing method | |
| TWI241187B (en) | Levodopa/carbidopa/entacapone pharmaceutical composition | |
| ES2509497T3 (en) | Controlled release formulation to prevent misuse | |
| WO2005037319A1 (en) | Composition for tablet rapidly disintegrable in mouth | |
| CN102917697A (en) | Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances | |
| TW200539902A (en) | Oral pharmaceutical compositions of timed-release particles and tablets quickly disintegrable in the oral cavity containing compositions thereof | |
| WO2009096560A1 (en) | Orally rapidly disintegrating tablet comprising imidafenacin | |
| JP5228359B2 (en) | Active ingredient particles, process for producing the same and orally disintegrating tablets | |
| CN102438597A (en) | A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants | |
| JP7361833B2 (en) | Orally disintegrating tablet of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid | |
| JP2008536922A (en) | Olanzapine pharmaceutical orally disintegrating tablets | |
| JP4939680B2 (en) | Solid preparation | |
| WO2023281089A2 (en) | Pharmaceutical composition comprising naproxen and paracetamol | |
| KR101277021B1 (en) | Oral controlled release double-layered rebamipide-contained formulation using gastro-retentive drug delivery system and process for the preparation thereof | |
| JP2003034655A (en) | Fast degradable solid tablet | |
| CN102307575A (en) | Aceclofenac-containing controlled-release oral drug preparations and their manufacturing process | |
| CN102727456B (en) | Drug port cavity disintegrating tablet and preparation method thereof | |
| US20060159751A1 (en) | Controlled release pharmaceutical compositions of carbidopa and levodopa | |
| EP2802311B1 (en) | Sublingual pharmaceutical composition containing an antihistamine agent and method for the preparation thereof | |
| TW202341973A (en) | Therapeutic compounds, formulations, and use thereof | |
| JP2010511023A (en) | Memantine formulation | |
| WO2017026950A1 (en) | Controlled release propiverine formulations | |
| JP6812104B2 (en) | Oral solid composition | |
| CN115429766B (en) | Icariin solid dispersion, compound medicine double-layer tablet, and preparation methods and applications thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20121010 |
|
| RJ01 | Rejection of invention patent application after publication |